Overview
BioPharma Credit : BPCR
BioPharma Credit plc provides investors with an opportunity to gain exposure to the fast growing life sciences industry, through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. BioPharma Credit’s primary objective is to generate predictable income for shareholders over the long term.
Once substantially invested, BioPharma Credit will target an annual dividend yield of 7 per cent. (calculated by reference to the Issue Price), and a net total return on NAV of 8 to 9 per cent. per annum in the medium term.
Pharmakon Advisors, the fund’s Investment Manager, was founded in 2009 and has invested US$1.3 billion in 20 transactions across four funds. The first three funds are now fully invested. Drawing upon the expertise and successful track record of Pharmakon Advisors, the fund enjoys access to its extensive, industry-focused knowledge and contacts to source, analyse and structure attractive investment opportunities.
Their website can be reached by clicking this link.
BPCR : BioPharma Credit
You can view our interviews with the company’s Fund Managers below:
24th June 2022: Pedro Gonzalez de Cosio – Weekly Show
Fundamentals
Price
Research History
-
14 Sep 2023
QuotedData’s Investment Companies Roundup – September 2023
September 2023 Monthly roundup | Investment companies Kindly sponsored by abrdn Winners and losers in August 2023 Share price total returns for investment companies were generally poor over August, with the best performing sector, Debt – Structured Finance, returning just 2.1%, with only a few sectors managing to eke out a positive total return. Funds […]
-
07 Dec 2022
QuotedData’s Investment Companies Roundup – December 2022
Investment Companies Monthly Roundup Kindly sponsored by abrdn December 2022 Monthly | Investment companies Winners and losers in November 2022 As discussed in this month’s economic and political roundup, lower US inflation triggered a fall in the US dollar and drove equity markets higher over November. The big surprise was the resurgence of Chinese markets […]
-
03 Nov 2022
QuotedData’s Investment Companies Roundup – November 2022
Investment Companies Monthly Roundup Kindly sponsored by Baillie Gifford and abrdn November 2022 Monthly | Investment companies Winners and losers in October 2022 Many equity markets recovered some of the ground lost in September. The swift departure of Liz Truss and her unfunded tax cuts helped the UK stock market and sterling. North America […]
-
06 Oct 2022
QuotedData’s Investment Companies Roundup – October 2022
Investment Companies Monthly Roundup Kindly sponsored by Baillie Gifford and abrdn October 2022 Monthly | Investment companies Winners and losers in September 2022 September’s median total share price return was -6.4% (+0.4% in August). The median NAV return over September was -1.2%. See Appendix 1 for a breakdown of how all the sectors have […]
-
06 Oct 2022
QuotedData's Economic and Political Monthly Roundup October 2022
Economic and Political Monthly Roundup Investment companies | Monthly | October 2022 A collation of recent insights on markets and economies taken from the comments made by chairs and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to […]
-
24 Jun 2022
Interview with Pedro Gonzalez de Cosio from BioPharma Credit
In this week’s show, James Carthew talked to Pedro Gonzalez de Cosio, manager of BioPharma Credit. If you were looking for the first part of QuotedData’s show, focused on the roundup of the week’s news, click here. If there is a guest speaker you’d particularly like to hear from, please email us. Additionally, if you […]
-
07 May 2020
QuotedData’s Investment Companies Roundup – May 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Table of contents New research In this issue Performance data Discounts and premiums Money in and out Major news stories Income Events Guide Appendix – Performance by sector full list New research Here is a list of research we published over April: An update note […]
-
17 Apr 2020
QuotedData’s Investment Companies Quarterly Review – First Quarter 2020
Investment Companies Quarterly Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Table of contents In this issue Performance data Positive movers Negative movers Discounts and premiums Getting more expensive Getting cheaper Money in and out Money in Money out Major news stories Upcoming Events New research The legal bit Unprecedented times We have knitted […]
-
07 Oct 2019
QuotedData’s economic roundup – October 2019
Economic & Political Roundup Kindly sponsored by Polar Capital and Allianz A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you […]
-
07 Aug 2019
QuotedData’s investment companies roundup – August 2019
Investment Companies Roundup New research Over July, we published notes on CQS New City High Yield, BlackRock Throgmorton, Strategic Equity Capital, Seneca Global Income & Growth, CG Asset Management, Standard Life Investments Property Income and Aberdeen New Dawn. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com. In this issue Performance data – appetite […]
-
19 Dec 2018
QuotedData's investment companies roundup - December 2018
QuotedData’s investment companies roundup – December 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of November 2018. Kindly sponsored by Baillie Gifford. Extract from ‘winners and losers’ The Californian wildfires took their toll on CatCo Reinsurance as it […]
-
13 Nov 2018
QuotedData's investment companies roundup - November 2018
QuotedData’s investment companies roundup – November 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of October 2018. Kindly sponsored by Baillie Gifford. Winners and losers in October In what was generally a miserable month for equity markets, Brazil shone […]
-
16 Oct 2018
Quarterly Investment Companies Roundup – Third Quarter 2018
Quarterly Investment Companies Roundup – Third Quarter 2018 Global equities delivered positive returns over the third quarter of 2018. This was principally because of strength in the US market. Political uncertainty and concerns about global trade held back other regions. Generally, government bond yields rose over the quarter. The UK equity market fell as the Bank of […]
-
12 Oct 2018
QuotedData’s investment companies roundup – October 2018
QuotedData’s investment companies roundup – October 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of August 2018. Kindly sponsored by Baillie Gifford. Money raised and returned in September Trian Investors 1 is a new fund that will adopt […]
-
18 Jul 2018
Quarterly Investment Companies Roundup – Second Quarter 2018
QUARTERLY INVESTMENT COMPANIES ROUNDUP – SECOND QUARTER 2018 Global equities markets rose in the second quarter of 2018, Markets were volatile, as positive economic data and encouraging company performances played off against geopolitical concerns. Yields from bond markets rose early in the quarter but fell back as investors turned to ‘safer’ investments. The threat of […]
-
11 May 2018
QuotedData’s investment companies roundup – May 2018
QuotedData investment companies roundup – May 2018 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of April 2018. Kindly sponsored by Baillie Gifford. India Capital Growth has experience a rebound in performance in the past month, as […]
-
25 Apr 2018
Quarterly investment companies roundup – First quarter 2018
Quarterly investment companies roundup – First quarter 2018 Quarterly investment companies roundup – First quarter 2018 – Global equity markets declined in the first quarter of 2018. Concerns about US interest rate rises were the feature of the first half of the quarter. However, worries about global trade took over in the second part, particularly […]
-
18 Jan 2018
QuotedData - 2017 review of the year
QuotedData – 2017 review of the year – Many commentators, including us, were wary going into 2017. In the event, economic growth and markets surprised on the upside: US markets hit new highs despite three interest rate rises. Perceived low/no growth areas such as Europe and Japan burst into life. Asia’s technology stocks surged. India’s […]
-
10 Jan 2018
QuotedData investment companies roundup – January 2018
QuotedData investment companies roundup – January 2018 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of December 2017. Kindly sponsored by Baillie Gifford. January Investment Companies Roundup Winners and losers in December Infrastructure India’s share price […]
-
11 Dec 2017
QuotedData investment companies roundup – December 2017
QuotedData investment companies roundup – December 2017 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of November 2017. Kindly sponsored by Baillie Gifford. December Investment Companies Roundup Money raised and returned in November There were no […]
-
10 Apr 2017
QuotedData investment companies roundup – April 2017
Our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of February 2017. Kindly sponsored by Baillie Gifford. April Investment Companies Roundup
News
-
05 Mar 2019
BioPharma Credit increases diversity of portfolio
Biopharma Credit increases diversity of portfolio – BioPharma Credit has published their annual report for the 2018 year. They have invested in three new companies totalling $494 million which greatly increased the scale and diversity of their portfolio. They have also deployed a further $164 million to support previous investment agreements. Tesaro Inc. was acquired […]
-
23 Jan 2019
BPCR gains windfall profit on Tesaro loan
BPCR boosted by windfall profit on Tesaro loan BioPharma Credit (BPCR), the LSE-listed investment vehicle that specialises in providing loans to biotech companies, is to receive a windfall profit from the early repayment of a $500m loan (of which it provided 64%) to Tesaro last year. This follows the completion of the acquisition of Tesaro, […]
-
20 Sep 2018
BioPharma Credit extends loan to Amicus
BioPharma Credit extends loan to Amicus – BioPharma Credit (BCPR) has entered into a $150m, five-year loan agreement with Amicus Therapeutics, a US-based biotech focused on rare disease. The senior secured loan will have a 2.0% additional consideration and bears interest at Libor plus 7.5% subject to a floor of 1% and certain caps. The loan is interest […]
-
02 May 2018
BioPharma Credit leads new $315m loan to Sebela
BioPharma Credit leads new $315m loan to Sebela BioPharma Credit (BPCR), the LSE-listed specialist life sciences debt investor, is to act as lead investor and collateral agent for a US$315m term loan to Sebela Pharmaceuticals, a US privately-held commercial-stage speciality pharmaceutical company focused on gastrointestinal, dermatology and women’s healthcare. BioPharma Credit will provide $194m of the loan principal […]
-
06 Apr 2018
BB Biotech may have to take hit on Incyte stake
BB Biotech may have to take hit on Incyte stake Switzerland’s BB Biotech (BBB.S) looks set to be in for a difficult month in terms of performance as a result of the negative result reported in a Phase III trial of a drug from Incyte Pharmaceuticals (Nasdaq:INCY), which was the trust’s third largest holding accounting […]
-
08 Mar 2018
$300m C share issue planned for BioPharma Credit
$300m C share issue planned for BioPharma Credit – BioPharma Credit has released its first annual results, covering the period from launch to 31 December 2017. The NAV at the end of the period was $1.0091, up from 98 cents immediately after launch. The original target was to pay a 4% dividend per annum. It declared interim […]
-
09 Feb 2018
BioPharma Credit makes $150m loan to NovoCure
BioPharma Credit makes $150m loan to NovoCure – BioPharma Credit has entered into a definitive term senior secured loan agreement for US$150 million with NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company with a current market capitalisation of approximately US$1.9 billion. The US$150 million loan will mature in February 2023 and bears interest at 9.0% […]
-
18 Dec 2017
Investment Trust Insider on Biotech
Investment Trust Insider on Biotech – inspired by the launch of our biotech news service on QuotedData, I wrote something for Citywire that looks at some of the exciting stories that have been published just in the last couple of weeks. James Carthew: biotech boom boosts generalist trusts This week I am returning to the […]
-
11 Dec 2017
BioPharma Credit acquires royalty interest in diabetes drugs
BioPharma Credit acquires royalty interest in diabetes drugs – In its third deal announced in rapid succession, BioPharma Credit has purchased from Royalty Pharma Investments (RPI) a 50% interest in a former Bristol-Myers Squibb-owned royalty stream on two AstraZeneca diabetes drugs. The royalty interested was acquired by RPI from Bristol Myers Squibb on 14 November 2017 and relates to sales of Onglyza […]
-
05 Dec 2017
BioPharma secures second deal for up to $200m
BioPharma secures second deal for up to $200m – BioPharma Credit PLC has announced that it and BioPharma Credit Investments IV, S.àr.L., entered into a definitive term loan agreement for up to US$200 million with Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a fully integrated biopharmaceutical company with a current market capitalisation of approximately US$1.0bn. Lexicon markets XERMELO® (teloristat […]
-
28 Nov 2017
Investment Trust Insider on the importance of diversification
Investment Trust Insider on the importance of diversification James Carthew: Herald shows Woodford and Biopharma the importance of diversification A month ago I wondered when Biopharma Credit (BPCR), the biggest investment company launch of the year, would get its flotation proceeds invested. Last week it took a big step towards answering this question by committing […]
-
22 Nov 2017
BioPharma Credit makes first major investment since IPO
BioPharma Credit makes first major investment since IPO – BioPharma Credit PLC says that, on 21 November 2017, it and BioPharma Credit Investments IV, S.àr.L.entered into a definitive loan agreement for up to US$500 million with TESARO, Inc. (NASDAQ: TSRO), a oncology focused biopharmaceutical company with a market capitalisation of US$4.5 billion. TESARO has commercial […]
-
31 Oct 2017
Investment Trust Insider on BioPharma Credit
Investment Trust Insider on BioPharma Credit James Carthew: don’t let Biopharma’s slow start give you the wrong impression (title by Citywire!!) This week I’m revisiting Biopharma Credit (BPCR) which I last wrote about at the end of March, when it listed having raised £610 million. As things stand, it still holds the top slot for […]